ICS 2023
Podium Short Oral Session 16 Male Lower Urinary Tract Symptoms 113 Roles of urine oxidative stress biomarkers and heart rate variability in BPH patients
Podium Video Session 37 Surgical Videos - Urogynaecology and Pain 308 Robot-Assisted Extravesical Vesicovaginal Fistula Repair
Open Discussion Session 36 Open Discussion ePosters 683 Urinary oxidative stress biomarker levels might be useful in identifying functional bladder disorders in women with frequency and urgency syndrome
ICS 2020
Open Discussion Session 8 ePoster 2 104 Videourodynamics analysis of the lower urinary tract dysfunctions in patients with chronic brain disorders
Open Discussion Session 8 ePoster 2 118 The urothelial cytoskeleton and cell proliferation protein expression in intersitial cystitis/bladder pain syndrome patients of different phenotype
Open Discussion Session 21 ePoster 5 316 Therapeutic efficacy of successful pelvic floor muscle exercise for dysfunctional voiding in women
Open Discussion Session 4 ePoster 1 36 Comparative study of therapeutic efficacy and safety between mirabegron 50mg QD and solifenacin 5mg QD in patients with overactive bladder due to central nervous system diseases such as cerebral vascular accident, Parkinson’s disease, and dementia – A multicenter, randomized study
Podium Short Oral Session 26 Male Voiding Dysfunction and LUTS 2 406 Treatment outcome of patients with CNS disorders and voiding dysfunction after bladder outlet surgery (TUIP, TURP, TUIBN)
Open Discussion Session 4 ePoster 1 41 Correlation of interstitial cystitis/bladder pain syndrome phenotype based on glomerulations and MBC subgroups and clinical characteristics
Podium Short Oral Session 38 Infection and Pot Pourri 590 Factors predicting the suboptimal response of the frontline medical treatment in women with dysfunctional voiding
Open Discussion Session 8 ePoster 2 95 Durability and effectiveness of transurethral incision of the bladder neck on women with urodynamically bladder neck dysfunction- a long-term follow up of additional procedure needed for voiding dysfunction
ICS 2019
Podium Session 1 Best Urology 1 Changes of lower urinary tract function after robotic-assisted radical prostatectomy- A urodynamic follow-up within one year
Podium Short Oral Session 8 Overactive Bladder 188 Will detrusor overactivity progress to detrusor underactivity? A longitudinal long-term urodynamic follow-up in patients with overactive bladder syndrome
Podium Short Oral Session 9 Urogynaecology 3 - Lower Urinary Tract Symptoms 191 Potential urinary biomarkers to diagnosis interstitial cystitis and overactive bladder
Podium Short Oral Session 17 Male Stress Urinary Incontinence 289 Urethral sphincter injections of platelet-rich plasma (PRP) in treatment of urinary incontinence due to intrinsic sphincteric deficiency refractory to conventional treatment
Open Discussion Session 18 E-Poster 2 295 Predictive factors for recovery of detrusor function and voiding efficiency after transurethral prostate surgery in men with detrusor acontractile
Open Discussion Session 18 E-Poster 2 386 The changes of urodynamic parameters and storage function in women with IC/BPS after long-term follow-up
Podium Short Oral Session 21 Pain Mediators and Interventions 440 The role of interstitial cells regeneration function in the bladder of interstitial cystitis and bladder pain syndrome and recurrent urinary tract infection
Podium Short Oral Session 21 Pain Mediators and Interventions 449 Therapeutic effects and changes of urine cytokines, functional proteins and growth factors in interstitial cystitis/bladder pain syndrome(IC/BPS) patients treated with repeat intravesical platelet rich plasma injections
Open Discussion Session 31 E-Poster 3 627 The baseline voiding and storage dysfunctions does not affect long-term treatment outcome in patients with interstitial cystitis/ bladder pain syndrome
Podium Short Oral Session 32 Urology - Best of the Rest 683 Long-term therapeutic efficacy and quality of life improvement in women with detrusor underactivity after transurethral incision of the bladder neck
ICS 2018
Podium Short Oral Session 10 Female Lower Urinary Tract Symptoms / Voiding Dysfunction 212 High incidence of voiding dysfunction in women with recurrent urinary tract infection
Podium Short Oral Session 10 Female Lower Urinary Tract Symptoms / Voiding Dysfunction 215 Transurethral incision of the bladder neck on female bladder neck dysfunction – long-term results and predictive factor in patients with detrusor underactivity
Podium Short Oral Session 12 Female Stress Urinary Incontinence 244 Long-term results in women with detrusor underactivity and stress urinary incontinence undergoing suburethral sling: predictive factors for successful outcome
Podium Short Oral Session 18 Bladder Outlet Obstruction 298 Change of Detrusor Contractility in Patients with and without Bladder Outlet Obstruction after over Ten-Year follow-up
Open Discussion Session 21 Open Discussion ePosters 423 Video-urodynamic Predictive Factors of Successful Urethral OnabotulinumtoxinA Treatment of Neurogenic or Non-neurogenic Urethral Sphincter Hyperactivity
Podium Short Oral Session 24 Basic Science: Overactive Bladder and Pain 458 The urothelial fibrogenesis and inflammation cytokines in patients of IC/BPS with different clinical phenotypes and symptom severity
Open Discussion Session 28 Open Discussion ePosters 523 Overactive Bladder Patients with More Severe Urgency had Higher Satisfaction with Mirabegron Dose Escalation from 25 mg to 50 mg
Open Discussion Session 28 Open Discussion ePosters 524 Adding antimuscarinic or mirabegron Increases the therapeutic effect in overactive bladder patients treated with 100 U onabotulinumtoxinA
Podium Short Oral Session 29 Interstitial Cystitis / Bladder Pain Syndrome 2 611 The role of viral infection in the pathogenesis of IC/BPS –A study of urinary virus in patients with IC/BPS and their clinical correlations
Podium Short Oral Session 6 Interstitial Cystitis / Bladder Pain Syndrome 1 64 Therapeutic effect of repeat platelet-rich-plasma intravesical injections for IC/BPS refractory to conventional treatment
Podium Short Oral Session 6 Interstitial Cystitis / Bladder Pain Syndrome 1 66 Anxiety Score Does not Influence Treatment Outcome in Patients with Interstitial Cystitis/Bladder Pain Syndrome
Non Discussion Abstract Session 36 Non Discussion Abstracts 705 Real World Long-Term Outcome in IC/BPS Patients with Multiple Treatments Modalities
Open Discussion Session 7 Open Discussion ePosters 78 Correlation of transient receptor potential cation channel subfamily V proteins in patients with different clinical severity of ketamine cystitis
Open Discussion Session 7 Open Discussion ePosters 79 The baseline videourodynamic findings and long-term therapeutic outcome in male IC/BPS patients
Open Discussion Session 7 Open Discussion ePosters 86 Sensory Protein Expression and Urethral Mucosal Dysfunction in the Pathogenesis of Male Bladder Neck Dysfunction and Benign Prostatic Obstruction
ICS 2017
Open Discussion Session 9 Open Discussion ePosters 1 131 Bladder management, patient satisfaction and complications in spinal cord injured patients after augmentation enterocystoplasty – A long-term follow-up
Open Discussion Session 9 Open Discussion ePosters 1 141 Histopathological characteristics of ketamine-associated uropathy and their clinical Association
Open Discussion Session 9 Open Discussion ePosters 1 167 Electron microscopic investigation of interstitial cystitis and KC: ulcer vs non-ulcer IC and their clinical correlation
Open Discussion Session 9 Open Discussion ePosters 1 190 Video-urodynamic predictive factors of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity
Podium Short Oral Session 12 Female Pelvic Medicine 245 EB virus in interstitial cystitis/bladder pain syndrome – an immunochemical study
Podium Short Oral Session 13 Pelvic Pain 249 Neurotrophin and fibrogenesis cytokines expression in ketamine cystitis bladders – correlation with clinical characteristics
Open Discussion Session 19 Open Discussion ePosters 2 320 Video-urodynamic characteristics of non-neurogenic, idiopathic underactive bladder in men – a comparison of men with normal tracing and bladder outlet obstruction
Open Discussion Session 19 Open Discussion ePosters 2 330 Long-term satisfaction and complications in women with ulcer type interstitial cystitis undergoing partial cystectomy and augmentation enterocystoplasty
Open Discussion Session 19 Open Discussion ePosters 2 354 Videourodynamic characteristics of detrusor underactivity in women with voiding dysfunction
Open Discussion Session 19 Open Discussion ePosters 2 361 Female bladder neck dysfunction -- a videourodynamic differential diagnosis among women with voiding dysfunction
Open Discussion Session 19 Open Discussion ePosters 2 396 Long-term success rate of suburethral sling procedure in patients with stress urinary incontinence and different bladder function
Podium Short Oral Session 24 Female Lower Urinary Tract Symptoms 1 479 Higher urge severity scale predicts the recurrence of overactive bladder symptoms after discontinuing mirabegron in patients with overactive bladder
Podium Short Oral Session 29 Urethra and Nocturia 516 Video-urodynamic predictive factors of successful urethral onabotulinumtoxinA treatment of neurogenic or non-neurogenic urethral sphincter hyperactivity
Podium Short Oral Session 30 Female Lower Urinary Tract Symptoms 2 533 Changes of urodynamics after suburethral sling might predict long-term success in women with stress urinary incontinence
Podium Short Oral Session 32 Neuromodulation and Intravesical Therapies 552 Comparative study of intravesical onabotulinumtoxinA injection for interstitial cystitis/bladder pain syndrome – bladder body versus trigonal injection
Podium Short Oral Session 32 Neuromodulation and Intravesical Therapies 553 Intravesical injections of platelet-rich plasma (PRP) in treatment of interstitial cystitis refractory to conventional treatment – A pilot study
Podium Short Oral Session 34 Basic Science 3 578 Urinary biomarkers in patients with detrusor underactivity with and without bladder function recovery
Open Discussion Session 35 Open Discussion ePosters 3 684 Predicting bladder outlet obstruction in men with persistent overactive bladder symptoms after medical treatment for lower urinary tract symptoms
Open Discussion Session 35 Open Discussion ePosters 3 689 Videourodynamic findings of interstitial cystitis and the association with clinical characteristics
Podium Short Oral Session 36 Female Lower Urinary Tract Symptoms and Neurourology 715 Detrusor onabotulinumtoxinA 200 U injection improved urothelial dysfunction but not altered urothelial sensory protein expressions in spinal cord injured patients
Non Discussion Abstract Session 41 Non Discussion Abstracts 783 Predictive factors for effective therapeutic response to alpha-blocker therapy in male patients with nocturia
Podium Short Oral Session 2 Lower Urinary Tract and Therapeutics 8 Therapeutic adding effect of mirabegron 50 mg in Asian OAB patients after initial treatment of mirabegron 25 mg – a randomized clinical trial
Non Discussion Abstract Session 41 Non Discussion Abstracts 918 Recovery of bladder function in male patients with non-neurogenic detrusor underactivity after treatment
Non Discussion Abstract Session 41 Non Discussion Abstracts 934 The role of stress associated receptor and neurotrophin expression in urothelium of interstitial cystitis
Non Discussion Abstract Session 41 Non Discussion Abstracts 937 Changes of urodynamics in patients with prostate cancer who underwent robotic-assisted radical prostatectomy and compared with laparoscopic radical prostatectomy
Non Discussion Abstract Session 41 Non Discussion Abstracts 975 Customized medication for mild to moderate male lower urinary tract symptoms based on International Prostate Symptom Score voiding to storage ratio
ICS 2016
Open Discussion Session 7 Open Discussion ePosters 124 Therapeutic efficacy and patient satisfaction of mirabegron shifting from stable antimuscarinics therapy in patients with overactive bladder syndrome – analysis of predictive factors
Open Discussion Session 7 Open Discussion ePosters 136 Videourodynamic studies of women with voiding dysfunction
Podium Express Session 13 Rapid Communications in Urology 219 Videourodynamic study of dysfunctional voiding in female voiding dysfunction – the role of urethral sphincter and pelvic floor muscles
Podium Express Session 13 Rapid Communications in Urology 239 Patient characteristics for different therapeutic strategies in the management ketamine cystitis
Podium Short Oral Session 18 Overactive Bladder and Paediatrics 278 Safety and therapeutic efficacy of mirabegron 25 mg in very old and frail patients with OAB and multiple comorbidities – comparison with younger patients
Podium Short Oral Session 18 Overactive Bladder and Paediatrics 279 Comparative study between different combination of mirabegron (25 or 50 mg) and antimuscarinics in treatment of OAB patients
Podium Short Oral Session 3 Urothelium and Sensation 28 Urothelial dysfunction and sensory protein expressions in Patients with Urological or Systemic Diseases and Hypersensitive Bladder
Open Discussion Session 19 Open Discussion ePosters 318 Adverse events of intravesical onabotulinumtoxinA injection between patients with overactive bladder and interstitial cystitis – different mechanism of action of Botox on bladder dysfunction
Podium Short Oral Session 4 Male Lower Urinary Tract Symptoms - Should We Treat Only the Prostate? 41 Therapeutic efficacy and safety of mirabegron monotherapy in male overactive bladder patients with and without bladder outlet obstruction
Podium Short Oral Session 24 Male Incontinence and Lower Urinary Tract Symptoms 446 Therapeutic efficacy of mirabegron 25 mg in patients with OAB due to central nervous system diseases such as Parkinson’s disease, minor stroke or early dementia
Podium Short Oral Session 25 Basic Insights into Lower Urinary Tract and Anal Sphincter Function 449 Urothelial dysfunction, suburothelial inflammation, and altered sensory protein expressions in men with bladder outlet obstruction and different bladder dysfunctions: a correlation with urodynamics
Podium Short Oral Session 26 Botulinum Toxin and the Lower Urinary Tract 463 Deficits of urothelial E-cadherin and zonula occludens-1 in chronic spinal cord injured bladders improved after repeated detrusor onabotulinumtoxinA injections
Podium Short Oral Session 26 Botulinum Toxin and the Lower Urinary Tract 466 Botulinum toxin urethral sphincter injection as treatment for non-neurogenic voiding dysfunction – A randomized, double-Blind, placebo-controlled study
Podium Short Oral Session 26 Botulinum Toxin and the Lower Urinary Tract 469 Efficacy and safety of botulinum toxin A treatment for patients with detrusor overactivity and inadequate contractility
Open Discussion Session 27 Open Discussion ePosters 541 Efficacy and safety of the use of mirabegron in patients with urodynamic detrusor overactivity and inadequate detrusor contractility
Podium Short Oral Session 28 Pelvic Pain and Urinary Tract Infection 554 Electron microscopic study in the urothelium of interstitial cystitis and ketamine related cystitis
Non Discussion Abstract Session 32 Non Discussion Abstracts 626 Urothelial functional protein and sensory receptors in patients with interstitial cystitis/bladder pain syndrome with and without Hunner’s lesion
Non Discussion Abstract Session 32 Non Discussion Abstracts 638 Urethral urothelial dysfunction and altered epithelial functional proteins and alpha-adrenoceptor in male patients with bladder neck dysfunction and BPH
Open Discussion Session 7 Open Discussion ePosters 69 Comprehensive review of histopathological findings of ketamine related cystitis and correlation with clinical parameters
Non Discussion Abstract Session 32 Non Discussion Abstracts 811 The role of bladder dysfunction in men with lower urinary tract symptoms refractory to alpha-blocker therapy – a video-urodynamic analysis
Non Discussion Abstract Session 32 Non Discussion Abstracts 812 Therapeutic efficacy of a new procedure combined with suburethral polypropylene mesh and cardiovascular patch for male urinary incontinence
Non Discussion Abstract Session 32 Non Discussion Abstracts 843 Clinical efficacy of mirabegron in the treatment of patients with nocturia predominant hypersensitive bladder
Non Discussion Abstract Session 32 Non Discussion Abstracts 853 Factors associated with therapeutic efficacy of intravesical onabotulinumtoxinA injection for overactive bladder syndrome
Non Discussion Abstract Session 32 Non Discussion Abstracts 876 Urodynamic characteristics of detrusor underactivity in male and female patients with voiding dysfunction
Non Discussion Abstract Session 32 Non Discussion Abstracts 878 A scale system to predict external sphincter dysfunction in male patients with voiding dysfunction refractory to α-blocker
Non Discussion Abstract Session 32 Non Discussion Abstracts 879 Female bladder neck dysfunction- a videourodynamic analysis of female voiding dysfunction
ICS 2015
Open Discussion Session 8 Open Discussion ePoster 108 Long-term Combined α-blockers and 5α–reductase Inhibitor in BPH Therapeutic Effects, Adherence, and Predictors for Withdrawal of Medication
Open Discussion Session 8 Open Discussion ePoster 112 Correlation of IPSS-Storage Score, OABSS and USS in Patients with OAB and Hypersensitive Bladder – Which One is the Best Score System for Assessing Severity of OAB ?
Podium Short Oral Session 10 Updates on the Use of Botulinum Toxin 171 Predictors of Adverse Events after OnabotulinumtoxinA Treatment for Patients with Overactive Bladder Syndrome
Podium Short Oral Session 4 Pelvic Pain Syndromes 19 Behind the Ulcer Type IC – An Analysis of the Correlation among Clinical Symptoms, Immunochemical Study, Computerized Tomography, and Histopathology Findings between Ulcer and Non-ulcer Type IC/BPS
Oral ePoster Session 16 Molecular Mechanisms of Sensation 225 Urothelial Dysfunction and Alterations of Sensory Protein Expressions in Bladder Mucosa in Patients with Idiopathic Detrusor Underactivity
Podium Session 19 What's New in Bladder Outlet Obstruction 252 The Potential Role of Urothelial Sensory Proteins in Patients with Bladder Outlet Obstruction and Different Bladder Dysfunctions
Podium Short Oral Session 5 Nocturia/Male LUTS 41 Bladder Dysfunction in Men with Lower Urinary Tract Symptoms Refractory to Alpha-blocker Therapy – A Videourodynamic Analysis and the Relationship with Age and Prostatic Volume
Podium Session 29 Nerves and Bladder Sensations 441 Immunoglobulin E plays an Important Role in the Pathogenesis of Bladder Pain Syndrome -- an Immunohistochemical Study of Painful Bladders
Oral ePoster Session 31 Biomarkers and Molecular Mechanisms 460 Urothelial Dysfunction and Protein Expressions in Patients with Chronic Kidney Diseaseand End-Stage Renal Disease and Different Sensory Dysfunction
Podium Short Oral Session 33 Frontiers in Education and Quality of Life 485 Therapeutic Safety and Efficacy of First-line Antimuscarinics for Elderly Patients with Overactive Bladder and Large Postvoid Residual Urine Volume (>100 mL)
Non Discussion Abstract Session 39 Non Discussion Abstracts 600 Factors to Predict Surgical Outcome of Transurethral Incision of Prostate in Men with Small BPH and Bladder Neck Dysfunction
Non Discussion Abstract Session 39 Non Discussion Abstracts 625 Predictor Factors for Successful Treatment of Solifenacin in Patients with Overactive Bladder
Non Discussion Abstract Session 39 Non Discussion Abstracts 652 Treatment Outcome in OAB Patients Receiving Antimuscarinic Therapy for more than One Year
Non Discussion Abstract Session 39 Non Discussion Abstracts 666 Videourodynamic Changes and the Impact on Urinary Continence after Laparoscopic Radical Prostatectomy
Open Discussion Session 8 Open Discussion ePoster 84 Single Institution Experience of Over 100 Cases of Augmentation Enterocystoplasty in the Patients with End-stage Bladder Diseases
ICS 2014
Podium Session 2 Should we perform a functional evaluation in Benign Prostatic Obstruction 10 Electrophysiology of the lower urinary tract in patients with detrusor underactivity– A necessary study to differentiate neuropathy and non-neuropathy before treatment
Open Discussion Poster Session 10 Imaging 107 Bladder wall thickness in computed tomography might be correlated with severity of inflammation in bladder pain syndrome
Open Discussion Poster Session 13 Pain & Sexual Dysfunction 154 Elevated serum immunoglobulin E and bladder Eosinophils infiltration suggest hypersensitivity might contribute to the pathogenesis of ketamine cystitis
Open Discussion Poster Session 13 Pain & Sexual Dysfunction 156 Immunohistochemistry study of ketamine related cystitis – A correlation with clinical characteristics with urothelial dysfunction and chronic inflammation
Open Discussion Poster Session 13 Pain & Sexual Dysfunction 167 Efficacy and safety of repeated Intravesical Onabotulinumtoxin-A injections for interstitial cystitis/painful bladder syndrome: long-term follow-up
Podium Poster Session 20 Lower Urinary Tract Symptoms in Women 1 335 Urothelial dysfunction and chronic Inflammation in diabetes mellitus patients with overactive bladder syndrome: An immunohistochemistry study
Podium Poster Session 22 Mechanisms Underlying Pain and Cystitis 349 Urothelial dysfunction and chronic inflammation in patients with bladder outlet obstruction and different bladder dysfunction
Podium Poster Session 22 Mechanisms Underlying Pain and Cystitis 350 Urothelial dysfunction and chronic inflammation in patients with chronic interstitial cystitis with and without Hunner’s lesion
Podium Poster Session 22 Mechanisms Underlying Pain and Cystitis 354 Proteomics of ketamine cystitis and interstitial cystitis – a way to search for different pathophysiology between diseases with similar bladder symptoms
Podium Poster Session 24 Innovative Therapies 373 Prospective randomized comparative study of intravesical onabotulinumtoxin A injection with different injection number for overactive bladder syndrome
Open Discussion Poster Session 34 Male 497 Urothelial dysfunction and chronic inflammation in patients with chronic kidney disease and end-stage renal disease – a clinical and histopathological study
Open Discussion Poster Session 37 Pharmacology 560 Therapeutic effects of intravesical onabotulinumtoxinA injection on IC/BPS refractory to conventional treatment - a randomized, double blind, placebo controlled study
Open Discussion Poster Session 37 Pharmacology 561 Botulinum toxin A urethral sphincter injection for non-obstructive voiding dysfunction – A randomized, double-blind, placebo control, multicenter study
Open Discussion Poster Session 37 Pharmacology 569 Intravesical instillation of Liposome encapsulated onabotulinumtoxinA for patients with overactive bladder – A pilot clinical study
Open Discussion Poster Session 37 Pharmacology 571 How long can antimuscarinic treatment be effective in treatment of overactive bladder – analysis of the predictive factors
Open Discussion Poster Session 37 Pharmacology 581 Combined intravesical trigonal and urethral injections of onabotulinumtoxinA in the treatment of patients with hypersensitive bladder and voiding dysfunction – a pilot study
Podium Poster Session 39 Lower Urinary Tract Symptoms in Women 2 621 Predictive factor for a successful surgical outcome of transurethral incision of bladder neck in female patients with detrusor underactivity
Podium Poster Session 39 Lower Urinary Tract Symptoms in Women 2 628 Lower urinary nerve growth factor levels indicate lower innate immunity and might predict recurrent urinary tract infection in women
Podium Poster Session 41 Neurophysiology and Bladder Dysfunction 650 Therapeutic efficacy and Safety of intravesical onabotulinumtoxinA 100 units injection on elderly patients with chronic central nervous system lesions and overactive bladder refractory to antimuscarinic therapy
ICS 2013
Podium Poster Session 12 Neurourology 1 113 UROTHELAIL DYSFUNCTION AND CHRONIC INFLAMMATION IN PATIENTS WITH SPINAL CORD INJURY OF DIFFERENT INJURY LEVEL AND CORRELATION WITH URODYNAMICS FINDINGS
Podium Poster Session 12 Neurourology 1 118 TRANSURETHRAL INCISION OF THE BLADDER NECK COULD IMPROVE VOIDING EFFICIENCY IN FEMALE PATIENTS WITH DETRUSOR UNDERACTIVITY
Podium Poster Session 17 Basic Science 4: Inflammation and Pain 153 INCREASED SUBUROTHELIAL NERVE FIBER AND PURINERGIC P2X3 RECEPTOR EXPRESSIONS IN PATIENTS WITH IDIOPATHIC DETRUSOR OVERACTIVITY AND THEIR RELATIONSHIP WITH BOTULINUM TOXIN A THERAPEUTIC OUTCOME
Podium Poster Session 18 Urodynamics 160 OVERACTIVE BLADDER IS A DYNAMIC SYNDROME -- A FIVE-YEAR LONGITUDINAL FOLLOW-UP OF THE CHANGES OF OVERACTIVE BLADDER SYMPTOMS, URODYNAMIC STUDY AND THE URINARY NERVE GROWTH FACTOR LEVELS
Podium Poster Session 28 Male 2 259 HETEROGENEITY OF MALE LUTS/BPH - ANALYSIS OF VIDEOURODYNAMIC DIAGNOSIS BASED ON TOTAL PROSTATE VOLUME AND AGE
Non Discussion Poster Session 34 357 SIMILARITY AND DISSIMILARITIES OF KETAMINE CYSTITIS AND INTERSTITIAL CYSTITIS - A PROTEOMICS ANALYSIS AMONG KETAMINE CYSTITIS, INTERSTITIAL CYSTITIS AND NORMAL BLADDERS
Podium Poster Session 7 Pain 54 REVISIT BLADDER GLOMERULATIONS AFTER HYDRODISTENTION- ARE GLOMERULATIONS A PATHOGNOMONIC SIGN FOR INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME? A PROSPECTIVELY SYSTEMATIC STUDY
Non Discussion Poster Session 34 552 REPEAT ONABOTULINUMTOXINA INJECTIONS PROVIDE BETTER THERAPEUTIC RESULTS THAN SINGLE INJECTION IN TREATMENT OF BLADDER PAIN SYNDROME
Non Discussion Poster Session 34 560 DECREASE OF URINARY NERVE GROWTH FACTOR BUT NOT BRAIN-DERIVED NEUROTRPOPHIC FACTOR IN PATIENTS WITH INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME SUCCESSFULLY TREATED WITH INTRAVESICAL HYALURONIC ACID
Non Discussion Poster Session 34 586 POST-TREATMENT OBJECTIVE VOIDING FUNCTION PARAMETERS ARE NOT ASSOCIATED WITH IMPROVEMENT OF QUALITY OF LIFE INDEX AFTER LONG-TERM COMBINATION THERAPY OF ALPHA-BLOCKER AND DUTASTERIDE FOR MEN WITH LUTS/BPH
Podium Poster Session 7 Pain 60 INTRAVESICAL ONABOTULINUMTOXINA INJECTIONS DO NOT BENEFIT PATIENTS WITH ULCER TYPE INTERSTITIAL CYSTITIS
Non Discussion Poster Session 34 600 CHANGES OF SUBUROTHELIAL INFLAMMATION AND JUNCTION PROTEIN E-CADHERIN IN CHRONIC SPINAL CORD INJURED BLADDERS AFTER DETRUSOR BOTULINUM TOXIN A INJECTIONS
Non Discussion Poster Session 34 624 DEVELOPMENT OF BLADDER GLOMERULATIONS AFTER HYDRODISTENSION IN PATIENTS WITH UPPER URINARY TRACT UROLITHIASIS SUGGESTING CROSS TALK AND BLADDER INFLAMMATION OCCUR BETWEEN UPPER AND LOWER URINARY TRACT
Non Discussion Abstract Session 35 Read By Title 687 REVISIT POTASSIUM CHLORIDE SENSITIVITY TEST - A SYSTEMATIC STUDY OF ITS ROLE ON LOWER URINARY TRACT DISEASES
Non Discussion Abstract Session 35 Read By Title 848 FLEXIBLY ADDING OXYBUTYNIN ON THE FIRST ANTIMUSCARINICS IN PATIENTS WITH REFRACTORY OVERACTIVE BLADDER - THERAPEUTIC EFFECTS AND COMPLICATIONS
Non Discussion Abstract Session 35 Read By Title 851 PREOPERATIVE URODYNAMIC PARAMETERS CANNOT PREDICT DELAY URINARY CONTINENCE AFTER LAPAROSCOPIC RADICAL PROSTATECTOMY
ICS 2012
Podium Session 21 Male II 186 ENHANCED ACCURATE DIAGNOSTIC RATE OF BLADDER OUTLET OBSTRUCTION IN MEN WITH LOWER URINARY TRACT SYMPTOMS USING INTERNATIONAL PROSTATIC SYMPTOM SCORE VOIDING/STORAGE RATIO IN ASSOCIATION WITH TOTAL PROSTATIC VOLUME AND MAXIMUM FLOW RATE
Podium Poster Session 4 Male I 20 A PROSPECTIVE RANDOMIZED STUDY OF TOLTERODINE AND DOXAZOSIN MONOTHERAPY AS THE FIRST LINE TREATMENT OF MALE LOWER URINARY TRACT SYMPTOMS WITH PREDOMINANT STORAGE SYMPTOMS BASED ON IPSS VOIDING TO STORAGE SUBSCORE RATIO
Podium Poster Session 23 Neurourology: Clinical III 205 LOWER URINARY TRACT DYSFUNCTION IN PATIENTS WITH CEREBELLAR VASCULAR ACCIDENT — A VIDEOURODYNAMIC ANALYSIS
Podium Poster Session 25 Urothelial Signalling 223 PRESENC OF SV2 AND SNAP-25 EXPRESSIONS IN BLADDER UROTHELIUM IN PATIENTS WITH OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS INDICATES THE POSSIBLE EFFECTIVE TREATMENT BY INTRAVESICAL INSTILLATION OF BOTULINUM TOXIN A
Podium Poster Session 26 Neurophysiology III 235 DOWN REGULATION OF APOPTOTIC AND INFLAMMATORY PROTEINS ARE ASSOCIATED WITH IMPROVED CLINICAL CHARACTERISTICS OF PATIENTS WITH INTERSTITIAL CYSTITIS AFTER REPEATED INTRAVESICAL BOTULINUM TOXIN A INJECTIONS
Podium Poster Session 4 Male I 25 AUGMENTATION ENTEROCYSTOPLASTY FOR END-STAGE BLADDER DISEASE DUE TO KETAMINE ABUSE
Podium Poster Session 29 Painful Bladder Syndromes/IC and QoL 272 INCREASED APOPTOSIS AND SUBUROTHELIAL INFLAMMATION IN PATIENTS WITH KETAMINE RELATED CYSTITIS – COMPARISON WITH INTERSTITIAL CYSTITIS AND CONTROLS
Podium Poster Session 29 Painful Bladder Syndromes/IC and QoL 274 DIFFERENT EXPRESSIONS OF THE BLADDER INFLAMMATION, APOPTOSIS AND BARRIER PROTEINS IN PATIENTS WITH BLADDER OUTLET OBSTRUCTION, INTERSTITIAL CYSTITIS, SPINAL CORD INJURY, RECURRENT URINARY TRACT INFECTION AND KETAMINE CYSTITIS SUGGEST A SIMILAR PATHOPHYSIOLOGY IS INVOLVED IN DIFFERENT BLADDER CONDITIONS
Podium Poster Session 29 Painful Bladder Syndromes/IC and QoL 276 DOWN REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER REPEATED INTRAVESICAL BOTULINUM TOXIN A INJECTIONS IS ASSOCIATED WITH IMPROVEMENTS OF CLINICAL SYMPTOMS AND BLADDER CAPACITY IN PATIENTS WITH INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
Non Discussion Poster Session 31 407 INTRAVESICAL BOTULINUM TOXIN A IS EFFECTIVE AND SAFE FOR PATIENTS WITH OVERACTIVE BLADDER AND INTRACEREBRAL LESION
Non Discussion Poster Session 31 414 BASELINE URODYNAMIC PARAMETERS DO NOT AFFECT THE TREATMENT OUTCOME OF INTRAVESICAL 100U ONABOTULINUMTOXINA INJECTION FOR PATIENTS WITH IDIOPATHIC DETRUSOR OVERACTIVITY
Non Discussion Poster Session 31 427 INCREASED SERUM C-REACTIVE PROTEIN LEVEL IS ASSOCIATED WITH INCREASED STORAGE LOWER URINARY TRACT SYMPTOMS SUGGESTING THE PRESENCE OF CHRONIC INFLAMMATION IN MEN WITH BENIGN PROSTATIC HYPERPLASIA
Non Discussion Poster Session 31 433 PREDICTIVE FACTORS FOR SUCCESSFUL FIRST-LINE ANTIMUSCARINICS MONOTHERAPY FOR MALE LUTS WITH PREDOMINANT STORAGE SYMPTOMS BASED ON IPSS VOIDING TO STORAGE SUBSCORE RATIO
Non Discussion Poster Session 31 463 INCREASED UROTHELIAL CELL APOPTOSIS AND CHRONIC INFLAMMATION MIGHT BE THE CAUSES OF RECURRENT URINARY TRACT INFECTION IN WOMEN
Non Discussion Poster Session 31 480 INCREASED PRO-INFLAMMATORY CYTOKINE AND CHEMOKINE EXPRESSIONS IN SERUM OF PATIENTS WITH INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
Non Discussion Poster Session 31 553 REPEATED INTRAVESICAL ONABOTULINUMTOXIN-A INJECTIONS ARE EFFECTIVE IN THE TREATMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME REFRACTORY TO CONVENTIONAL TREATMENT
Non Discussion Poster Session 31 604 PREDICTIVE FACTORS FOR SUCCESSFUL BOTULINUM TOXIN A INJECTIONS FOR REFRACTORY INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME
Podium Poster Session 7 LUTS Etiology and Treatment 61 ELEVATION OF SERUM HEPATIC GROWTH FACTOR AND NERVE GROWTH FACTOR IN PATIENTS WITH OVERACTIVE BLADDER IMPLIES NERVE FIBERS INCREASING IN URINARY BLADDER
Podium Poster Session 7 LUTS Etiology and Treatment 73 INCREASED RISK OF LARGE POSTVOID RESIDUAL URINE AND LOWER LONG-TERM SUCCESS RATE IN FRAIL PATIENTS 70 YEARS AND OLDER AFTER INTRAVESICAL ONABOTULINUMTOXIN A INJECTION FOR REFRACTORY IDIOPATHIC DETRUSOR OVERACTIVITY
Podium Poster Session 8 Neurourology: Clinical I 75 EFFICACY AND SAFETY OF INTRAVESICAL ONABOTULIUMTOXIN A INJECTION ON PATIENTS WITH IDIOPATHIC DETRUSOR OVERACTIVITY AND DIABETES MELLITUS
Podium Poster Session 8 Neurourology: Clinical I 77 DIFFERENCE OF THE THERAPEUTIC EFFECT BETWEEN REPEATED DETRUSOR INJECTIONS OF 200 U AND 300 U BOTULINUM TOXIN A ON GLOMERULAR FILTRATION RATE IN CHRONIC SPINAL CORD INJURED PATIENTS
ICS 2011
Podium Poster Session 3 Treatments for Stress Urinary Incontinence 24 Position of Suburethral Sling at the Bladder Neck May Predict a Higher Recurrent Rate of SUI
Non Discussion Poster Session 29 334 Chronic inflammation but not urothelium dysfunction in patients with overactive bladder syndrome
Non Discussion Abstract Session 31 Read by Title 720 International Prostate Symptom Score is not Suitable for Assessing Emptying Lower Urinary Tract Dysfunction in Women
Non Discussion Abstract Session 31 Read by Title 771 Comparison of intravesical hyaluronic acid instillation with different regimens for interstitial cystitis/painful bladder syndrome
ICS/IUGA 2010
Podium Poster Session 19 Overactive Bladder Pelvic Floor 187 Bladder Base Injection is as Effective and Safe as Bladder Body injection of Botulinum Toxin A for Idiopathic Detrusor Overactivity
Podium Poster Session 25 Pathophysiology and Quality of Life 231 Increased Apoptosis and Decreased Junction Protein Expression of Urothelium due to Suburothelial Inflammation in Patients with Interstitial Cystitis/Painful Bladder Syndrome
Non Discussion Poster Session 31 359 Mast cells infiltration is increased in the bladder tissue of patients with overactive bladder symptoms and Interstitial cystitis/painful bladder syndrome
Non Discussion Poster Session 31 455 Measurement of IPSS-storage and IPSS-empty Subscores Could Help to Differentiate Bladder related and Urethral-related Conditions in Men with LUTS for Initial Medical Treatment
Non Discussion Poster Session 31 527 Effect of Repeat Botulinum Toxin A Detrusor Injection on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients
Non Discussion Poster Session 31 532 Predictive Factors of Satisfactory Response to Detrusor Botulinum Toxin A Injection for Neurogenic Detrusor Overactivity and Detrusor Sphincter Dyssynergia In Spinal Cord Injured Patients
Podium Poster Session 8 Female LUTS, Clinical and Basic Science 61 Urinary Nerve Growth Factor in Women with Overactive Bladder Syndrome
ICS 2009
Podium Poster Session 18 Detrusor Overactivity Non-Clinical 186 Urinary Nerve Growth Factor is a Better Biomarker than Detrusor Wall Thickness for the Assessment of Overactive Bladder with Incontinence
ICS 2008
Non Discussion Poster Session 19 283 Treatment of urethral dysfunction by urethral injections of botulinum toxin A in male patients presented with lower urinary tract symptoms but without bladder outlet obstruction
ICS 2007
Podium Session 14 Male Voiding Dysfunction:Room: Grote Zaal - Chairs: Klaus Hofner & Bert Messelink 111 Videourodynamic Analysis of Pathophysiology of Men with Both Storage and Voiding Lower Urinary Tract Symptoms
Non Discussion Poster Session 17 267 Causes of Failed Urethral Botulinum Toxin A Treatment for Voiding Dysfunction